Ampersand Capital Partners Acquires Purna Pharmaceuticals
February 12, 2026
Ampersand Capital Partners acquired Purna Pharmaceuticals, a Belgian contract development and manufacturing provider of liquid and semi-solid pharmaceutical dosage forms. The investment positions Purna to collaborate with Ampersand portfolio company MedPharm to create a trans‑Atlantic topical and transdermal development and manufacturing offering; Creafund, Purna's prior investor, supported the company for more than a decade and was referenced in the transaction announcement.
- Buyers
- Ampersand Capital Partners
- Targets
- Purna Pharmaceuticals
- Sellers
- Creafund
- Industry
- Pharmaceuticals
- Location
- Antwerp, Belgium
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Ampersand Capital Partners Invests in Alliance Pharma
November 18, 2021
Healthcare Services
Ampersand Capital Partners has made a growth equity investment in Alliance Pharma, a Malvern, Pennsylvania–based bioanalytical CRO. The funding will support Alliance’s expansion of global reach, scientific capabilities, and operational capacity while founder Frank Li remains a significant shareholder.
-
Ampersand Capital Partners Acquires CurTec
July 21, 2025
Packaging
Ampersand Capital Partners has acquired CurTec Group B.V., a Netherlands-based manufacturer of high-performance plastic packaging for pharmaceutical and specialty chemical applications, from Bencis Capital Partners in partnership with CurTec management. The deal positions Ampersand to scale CurTec's U.S. footprint, accelerate product innovation, and expand capacity and commercial capabilities to serve pharma and specialty chemicals customers globally.
-
Ampersand Capital Partners Majority Recapitalizes Phosphorex
August 25, 2022
Healthcare Services
Ampersand Capital Partners completed a majority recapitalization of Phosphorex to provide growth capital enabling the company to build out a 30,000 sq. ft. facility and establish cGMP manufacturing capabilities for lipid nanoparticles, microspheres and other drug-delivery platforms. The investment positions Phosphorex to expand from development and analytical services into end-to-end CDMO manufacturing to better serve pharmaceutical and biotechnology clients.
-
Ampersand Capital Partners Invests in AnaBios Corporation
June 7, 2022
Healthcare Services
Ampersand Capital Partners has made a growth equity investment in San Diego-based AnaBios Corporation, a preclinical contract research organization specializing in translational research using human tissues. The investment will be used to expand AnaBios’s capabilities, therapeutic area coverage and global reach to support more successful drug discovery and development programs.
-
Permira Makes Substantial Growth Investment in PharmaCord
June 6, 2024
Healthcare Services
Permira (via a company backed by Permira funds) has signed a definitive agreement to make a substantial growth investment in PharmaCord, a Jeffersonville, Indiana-based tech-enabled patient services provider for specialty pharmaceuticals. Founder and CEO Nitin Sahney and the management team will remain significant investors and operators; terms were not disclosed and the deal is expected to close by Q4 2024.
-
MedPharm and Tergus Pharma Merge to Create Topical & Transdermal CDMO Leader
July 8, 2024
Pharmaceuticals
MedPharm and Tergus Pharma have merged and will operate under the MedPharm name to create an integrated, end-to-end topical and transdermal CDMO. Ampersand Capital Partners and Bourne Partners Strategic Capital assume majority ownership of the combined company while Great Point Partners retains a significant minority stake; Michael Kane is appointed CEO and Patrick Walsh remains Executive Chairman.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.